Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CIDP.

Kine Sciences, a biopharmaceutical company, has announced that the first patient has been dosed in its Phase 1b/2a clinical study of KINE-101 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). KINE-101 is a novel nanopeptide that activates Treg cells to control immune responses. The Phase 1 study of KINE-101, which demonstrated a good safety profile, was completed successfully in October 2023. KINE-101 is also being developed for other indications, including Inflammatory Bowel Disease, Rheumatoid Arthritis, and Non-Alcoholic Steatohepatitis. [Extracted from the article]